Assessment of the systemic distribution of a bioconjugated anti-Her2 magnetic nanoparticle in a breast cancer model by means of magnetic resonance imaging

被引:0
|
作者
L. F. E. Huerta-Núñez
G. Cleva Villanueva-Lopez
A. Morales-Guadarrama
S. Soto
J. López
J. G. Silva
N. Perez-Vielma
E. Sacristán
Marco E. Gudiño-Zayas
C. A. González
机构
[1] Universidad del Ejercito y FAM/EMGS-Laboratorio Multidisciplinario de Investigación,Departamento de Medicina Experimental, Facultad de Medicina
[2] Instituto Politécnico Nacional-Escuela Superior de Medicina-Sección Investigación y Posgrado,undefined
[3] Centro Nacional de Investigacion en Imagenologia e Instrumentacion Medica-Universidad Autónoma,undefined
[4] Instituto Politécnico Nacional - Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás (CICS-UST),undefined
[5] UNAM,undefined
来源
关键词
Breast cancer; Magnetic nanoparticles; Anti-Her2; Systemic distribution; Magnetic resonance imaging; Nanomedicine;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this study was to determine the systemic distribution of magnetic nanoparticles of 100 nm diameter (MNPs) coupled to a specific monoclonal antibody anti-Her2 in an experimental breast cancer (BC) model. The study was performed in two groups of Sprague–Dawley rats: control (n = 6) and BC chemically induced (n = 3). Bioconjugated “anti-Her2-MNPs” were intravenously administered, and magnetic resonance imaging (MRI) monitored its systemic distribution at seven times after administration. Non-heme iron presence associated with the location of the bioconjugated anti-Her2-MNPs in splenic, hepatic, cardiac and tumor tissues was detected by Perl’s Prussian blue (PPB) stain. Optical density measurements were used to semiquantitatively determine the iron presence in tissues on the basis of a grayscale values integration of T1 and T2 MRI sequence images. The results indicated a delayed systemic distribution of MNPs in cancer compared to healthy conditions with a maximum concentration of MNPs in cancer tissue at 24 h post-infusion.
引用
收藏
相关论文
共 50 条
  • [21] Prospect for anti-HER2 receptor therapy in breast cancer
    Brand, FX
    Ravanel, N
    Gauchez, AS
    Pasquier, D
    Payan, R
    Fagret, D
    Mousseau, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 463 - 470
  • [22] Anti-HER2 therapy for breast cancer in older patients
    Goldner, Marcelle
    Franzoi, Maria A.
    Lago, Lissandra D.
    Ponde, Noam
    FUTURE ONCOLOGY, 2020, 16 (19) : 1393 - 1407
  • [23] Anti-HER2 Therapy in Elderly Breast Cancer Patients
    Sawaki, Masataka
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (04) : 263 - 266
  • [24] Current and future anti-HER2 therapy in breast cancer
    Vrbic, S.
    Pejcic, I.
    Filipovic, S.
    Kocic, B.
    Vrbic, M.
    JOURNAL OF BUON, 2013, 18 (01): : 4 - 16
  • [25] Developing anti-HER2 vaccines: Breast cancer experience
    Al-Awadhi, Aydah
    Lee Murray, James
    Ibrahim, Nuhad K.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (09) : 2126 - 2132
  • [26] Advances in anti-HER2 therapy in metastatic breast cancer
    Yao, Minya
    Fu, Peifen
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [27] Optimising anti-HER2 therapy in early breast cancer
    Piccart, M.
    Bedard, P.
    de Azambuja, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 34 - 34
  • [28] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [29] CRANIAL MAGNETIC RESONANCE IMAGING (MRI) IN THE STAGING OF HER2-POSITIVE BREAST CANCER PATIENTS
    Kaplan, M. A.
    Inal, A.
    Kucukoner, M.
    Urakci, Z.
    Ekici, F.
    Firat, U.
    Isikdogan, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 137 - 137
  • [30] Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+breast cancer
    Whisenant, Jennifer G.
    Ayers, Gregory D.
    Loveless, Mary E.
    Barnes, Stephanie L.
    Colvin, Daniel C.
    Yankeelov, Thomas E.
    MAGNETIC RESONANCE IMAGING, 2014, 32 (03) : 245 - 249